RNAZ - Transcode Therapeutics, Inc.
9.6
0.270 2.813%
Share volume: 11,008
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$9.33
0.27
0.03%
View ratios
| Fiscal Date | 06-30-2024 | 09-30-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 08-14-2024 | 11-14-2024 | 05-14-2025 | 11-14-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | |||
| Operating expenses | 5.114 M | 2.165 M | 3.171 M | 4.561 M | |
| Selling general and admin | 2.032 M | 938.026 K | 951.652 K | 1.400 M | |
| Research and development | 3.082 M | 1.227 M | 2.220 M | 3.161 M | |
| Total expenses | 5.114 M | 2.165 M | 3.171 M | 4.561 M | |
| -57.66% | 46.45% | 43.83% | |||
| Operating income | -5.114 M | -2.165 M | -3.171 M | -4.561 M | |
| Ebit | -5.187 M | -2.311 M | -12.085 M | -4.850 M | |
| Pretax income | -5.191 M | -2.321 M | -12.085 M | -4.856 M | |
| -55.28% | 420.61% | -59.82% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -5.191 M | -2.321 M | -12.085 M | -4.856 M | |
| 55.28% | -420.61% | 59.82% |